By consolidating available evidence, this meta-analysis aims to support clinicians in evidence-based decision-making, by analyzing the efficacy and safety of SYK and BTK inhibitors for adult patients with ITP. Here, SYK is linked to autoimmune thrombocytopenic purpura.